메뉴 건너뛰기




Volumn 21, Issue 8, 2010, Pages 1381-1389

Bevacizumab increases risk for severe proteinuria in cancer patients

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; VASCULOTROPIN;

EID: 77955638572     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2010020167     Document Type: Review
Times cited : (201)

References (44)
  • 1
    • 0034471796 scopus 로고    scopus 로고
    • Molecular mechanisms of tumor angiogenesis and tumor progression
    • DOI 10.1023/A:1006414621286
    • Cavallaro U, Christofori G: Molecular mechanisms of tumor angiogenesis and tumor progression. J Neurooncol 50: 63-70, 2000 (Pubitemid 32166291)
    • (2000) Journal of Neuro-Oncology , vol.50 , Issue.1-2 , pp. 63-70
    • Cavallaro, U.1    Christofori, G.2
  • 2
    • 0036984640 scopus 로고    scopus 로고
    • Role of angiogenesis in tumor growth and metastasis
    • Folkman J: Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29: 15-18, 2002
    • (2002) Semin Oncol , vol.29 , pp. 15-18
    • Folkman, J.1
  • 3
    • 14644440555 scopus 로고    scopus 로고
    • Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis
    • DOI 10.1200/JCO.2005.06.081
    • Hicklin DJ, Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23: 1011-1027, 2005 (Pubitemid 46202320)
    • (2005) Journal of Clinical Oncology , vol.23 , Issue.5 , pp. 1011-1027
    • Hicklin, D.J.1    Ellis, L.M.2
  • 4
    • 13444278498 scopus 로고    scopus 로고
    • Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies
    • Gerber HP, Ferrara N: Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65: 671-680, 2005
    • (2005) Cancer Res , vol.65 , pp. 671-680
    • Gerber, H.P.1    Ferrara, N.2
  • 6
    • 33846638744 scopus 로고    scopus 로고
    • Risks of Proteinuria and Hypertension with Bevacizumab, an Antibody Against Vascular Endothelial Growth Factor: Systematic Review and Meta-Analysis
    • DOI 10.1053/j.ajkd.2006.11.039, PII S0272638606018336
    • Zhu X, Wu S, Dahut WL, Parikh CR: Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 49: 186-193, 2007 (Pubitemid 46178407)
    • (2007) American Journal of Kidney Diseases , vol.49 , Issue.2 , pp. 186-193
    • Zhu, X.1    Wu, S.2    Dahut, W.L.3    Parikh, C.R.4
  • 12
    • 40749158416 scopus 로고    scopus 로고
    • Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM)
    • Karrison T, Kindler HL, Gandara DR, Lu C, Guterz TL, Nichols K, Chen H, Stadler WM, Vokes EE: Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM). ASCO Meeting Abstracts 25: 7526, 2007
    • (2007) ASCO Meeting Abstracts , vol.25 , pp. 7526
    • Karrison, T.1    Kindler, H.L.2    Gandara, D.R.3    Lu, C.4    Guterz, T.L.5    Nichols, K.6    Chen, H.7    Stadler, W.M.8    Vokes, E.E.9
  • 13
    • 35548941394 scopus 로고    scopus 로고
    • A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B CALGB
    • Cancer & Leukemia Group B
    • Kindler HL, Niedzwiecki D, Hollis D, Oraefo E, Schrag D, Hurwitz H, McLeod HL, Mulcahy MF, Schilsky RL, Goldberg RM, Cancer & Leukemia Group B: A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB. ASCO Meeting Abstracts 25: 4508, 2007
    • (2007) ASCO Meeting Abstracts , vol.25 , pp. 4508
    • Kindler, H.L.1    Niedzwiecki, D.2    Hollis, D.3    Oraefo, E.4    Schrag, D.5    Hurwitz, H.6    McLeod, H.L.7    Mulcahy, M.F.8    Schilsky, R.L.9    Goldberg, R.M.10
  • 14
    • 54249120945 scopus 로고    scopus 로고
    • Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO
    • Miles D, Chan A, Romieu G, Dirix LY, Cortes J, Pivot X, Tomczak P, Taran T, Harbeck N, Steger GG: Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. ASCO Meeting Abstracts 26: LBA1011, 2008
    • (2008) ASCO Meeting Abstracts , vol.26
    • Miles, D.1    Chan, A.2    Romieu, G.3    Dirix, L.Y.4    Cortes, J.5    Pivot, X.6    Tomczak, P.7    Taran, T.8    Harbeck, N.9    Steger, G.G.10
  • 18
    • 34248173883 scopus 로고    scopus 로고
    • Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200
    • Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB 3rd: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25: 1539-1544, 2007
    • (2007) J Clin Oncol , vol.25 , pp. 1539-1544
    • Giantonio, B.J.1    Catalano, P.J.2    Meropol, N.J.3    O'Dwyer, P.J.4    Mitchell, E.P.5    Alberts, S.R.6    Schwartz, M.A.7    Benson III, A.B.8
  • 26
    • 68749117496 scopus 로고    scopus 로고
    • Nephrotic-range proteinuria in a patient with a renal allograft treated with sorafenib for metastatic renal-cell carcinoma
    • Jonkers IJ, van Buren M: Nephrotic-range proteinuria in a patient with a renal allograft treated with sorafenib for metastatic renal-cell carcinoma. Clin Exp Nephrol 13: 397-401, 2009
    • (2009) Clin Exp Nephrol , vol.13 , pp. 397-401
    • Jonkers, I.J.1    Van Buren, M.2
  • 27
    • 39649122843 scopus 로고    scopus 로고
    • A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib
    • Patel TV, Morgan JA, Demetri GD, George S, Maki RG, Quigley M, Humphreys BD: A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst 100: 282-284, 2008
    • (2008) J Natl Cancer Inst , vol.100 , pp. 282-284
    • Patel, T.V.1    Morgan, J.A.2    Demetri, G.D.3    George, S.4    Maki, R.G.5    Quigley, M.6    Humphreys, B.D.7
  • 29
    • 2442707596 scopus 로고    scopus 로고
    • The role of vascular endothelial growth factor (VEGF) in renal pathophysiology
    • Schrijvers BF, Flyvbjerg A, De Vriese AS: The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 65: 2003-2017, 2004
    • (2004) Kidney Int , vol.65 , pp. 2003-2017
    • Schrijvers, B.F.1    Flyvbjerg, A.2    De Vriese, A.S.3
  • 31
    • 33846484966 scopus 로고    scopus 로고
    • Renal thrombotic microangiopathy caused by anti-VEGF antibody treatment for metastatic renal-cell carcinoma
    • Frangie C, Lefaucheur C, Medioni J, Jacquot C, Hill GS, Nochy D: Renal thrombotic microangiopathy caused by anti-VEGF antibody treatment for metastatic renal-cell carcinoma. Lancet Oncol 8: 177-178, 2007
    • (2007) Lancet Oncol , vol.8 , pp. 177-178
    • Frangie, C.1    Lefaucheur, C.2    Medioni, J.3    Jacquot, C.4    Hill, G.S.5    Nochy, D.6
  • 32
    • 34247597779 scopus 로고    scopus 로고
    • Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma
    • Roncone D, Satoskar A, Nadasdy T, Monk JP, Rovin BH: Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma. Nat Clin Pract Nephrol 3: 287-293, 2007
    • (2007) Nat Clin Pract Nephrol , vol.3 , pp. 287-293
    • Roncone, D.1    Satoskar, A.2    Nadasdy, T.3    Monk, J.P.4    Rovin, B.H.5
  • 33
    • 56549115248 scopus 로고    scopus 로고
    • Glomerular disease related to anti-VEGF therapy
    • Stokes MB, Erazo MC, D'Agati VD: Glomerular disease related to anti-VEGF therapy. Kidney Int 74: 1487-1491, 2008
    • (2008) Kidney Int , vol.74 , pp. 1487-1491
    • Stokes, M.B.1    Erazo, M.C.2    D'Agati, V.D.3
  • 35
    • 33751403599 scopus 로고    scopus 로고
    • Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group
    • discussion 174
    • Schips L, Dalpiaz O, Lipsky K, Langner C, Rehak P, Puerstner P, Pummer K, Zigeuner R: Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group. Eur Urol 51: 168-173, discussion 174, 2007
    • (2007) Eur Urol , vol.51 , pp. 168-173
    • Schips, L.1    Dalpiaz, O.2    Lipsky, K.3    Langner, C.4    Rehak, P.5    Puerstner, P.6    Pummer, K.7    Zigeuner, R.8
  • 36
    • 0021070402 scopus 로고
    • Use of single voided urine samples to estimate quantitative proteinuria
    • Ginsberg JM, Chang BS, Matarese RA, Garella S: Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med 309: 1543-1546, 1983
    • (1983) N Engl J Med , vol.309 , pp. 1543-1546
    • Ginsberg, J.M.1    Chang, B.S.2    Matarese, R.A.3    Garella, S.4
  • 37
  • 38
    • 0347453077 scopus 로고    scopus 로고
    • Selecting and appraising studies for a systematic review
    • Meade MO, Richardson WS: Selecting and appraising studies for a systematic review. Ann Intern Med 127: 531-537, 1997
    • (1997) Ann Intern Med , vol.127 , pp. 531-537
    • Meade, M.O.1    Richardson, W.S.2
  • 39
    • 12344312699 scopus 로고    scopus 로고
    • Available at: Accessed September 15, 2009
    • National Cancer Institute: Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Available at: http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC. aspx. Accessed September 15, 2009
    • Common Terminology Criteria for Adverse Events V3.0 (CTCAE)
  • 40
    • 85190701314 scopus 로고    scopus 로고
    • Available at Accessed September 1, 2009
    • Biostat I: Comprehensive Meta-analysis. 2006. Available at www.meta-analysis.com. Accessed September 1, 2009
    • (2006) Biostat I: Comprehensive Meta-analysis
  • 42
    • 66149133167 scopus 로고    scopus 로고
    • International multi-centre randomised Phase II/III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for metastatic colorectal cancer (mCRC): Final safety analysis of the AGITG MAX trial
    • Price TJ, Gebski V, van Hazel GA, Robinson BA, Broad A, Ganju V, Cunningham D, Wilson K, Tunney V, Tebbutt NC: International multi-centre randomised Phase II/III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for metastatic colorectal cancer (mCRC): Final safety analysis of the AGITG MAX trial. ASCO Meeting Abstracts 26: 4029, 2008
    • (2008) ASCO Meeting Abstracts , vol.26 , pp. 4029
    • Price, T.J.1    Gebski, V.2    Van Hazel, G.A.3    Robinson, B.A.4    Broad, A.5    Ganju, V.6    Cunningham, D.7    Wilson, K.8    Tunney, V.9    Tebbutt, N.C.10
  • 43
    • 36048982143 scopus 로고    scopus 로고
    • Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer
    • Herbst RS, O'Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L, Melnyk O, Ramies D, Lin M, Sandler A: Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 25: 4743-4750, 2007
    • (2007) J Clin Oncol , vol.25 , pp. 4743-4750
    • Herbst, R.S.1    O'Neill, V.J.2    Fehrenbacher, L.3    Belani, C.P.4    Bonomi, P.D.5    Hart, L.6    Melnyk, O.7    Ramies, D.8    Lin, M.9    Sandler, A.10
  • 44
    • 0037208589 scopus 로고    scopus 로고
    • Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer
    • Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21: 60-65, 2003
    • (2003) J Clin Oncol , vol.21 , pp. 60-65
    • Kabbinavar, F.1    Hurwitz, H.I.2    Fehrenbacher, L.3    Meropol, N.J.4    Novotny, W.F.5    Lieberman, G.6    Griffing, S.7    Bergsland, E.8


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.